The woundcare market has long been a large and highly...

The woundcare market has long been a large and highly competitive market. In that regard, little has changed in recent years.

Problem is, most products in the market have limited efficacy in resolving persistent wounds, hence the market opportunity pursured by FTT.

There are plenty of other wannabe players out there in clinic as well, nothing changed there either. Some will prove clinical benefits, others won't, just like FTT is attempting to do.

The end game has always been to build enough clinical evidence to sufficiently pique the interest of a partner. J&J might want to maintain their market position, Coloplast may want to tear open new markets. As long established and not especially innovative behemoths, its more likely they will seek a disruptive technology to integrate into their existing products.

VLA just got bought by Merck. Their overnight success was built on clinical studies for nigh on 15 years, the last 2 in partnership with Merck and Bristol Myers Squibb. Sometimes the deal comes off and sometimes (like BNO), you just got to wait till they are sufficiently ready to go.